Is Mounjaro Safe During Breastfeeding?

Step 1: understand why 'not recommended' is the position

When a medicine has no human lactation data, regulators and prescribers fall back on a precautionary position: if risk to the infant cannot be quantified, the medicine should not be used. That is the situation with tirzepatide. Rodent studies found the drug present in milk, and given that Mounjaro slows gastric emptying and affects appetite signalling, any exposure during the critical early months of an infant's development is a concern that cannot simply be dismissed. The NHS patient information page for tirzepatide is explicit: Mounjaro should not be taken while breastfeeding.

This is not unique to tirzepatide. Semaglutide (the medicine in Wegovy) carries the same guidance. The honest position is that GLP-1 class medicines as a group lack the lactation safety evidence that would allow a prescriber to say the risk is acceptable. Our clinical team reviews every consultation individually, but breastfeeding is a clear contraindication for this medicine.

If you are currently on Mounjaro from a previous prescription and have since started breastfeeding, speak to a GP or pharmacist promptly. Do not continue on the assumption that ongoing use is fine because it was prescribed before.

Step 2: know what 'not suitable right now' means for your plans

Not being eligible while breastfeeding does not close the door permanently. Many women ask how long after stopping breastfeeding they would need to wait before starting treatment. The SmPC does not specify a fixed washout period for this transition, so this is genuinely a question for your GP or a prescriber who can review your full health record. What matters clinically is that you are no longer breastfeeding and that the prescriber has a clear picture of your current weight, BMI and any weight-related health conditions before making a recommendation.

You can read about the broader side-effect profile of Mounjaro in the meantime, and the full Mounjaro overview covers how the medicine works, its dual GIP and GLP-1 mechanism, and what the clinical trials found. Understanding the treatment before you are eligible is a sensible use of time. Separately, the general weight-loss treatment overview sets out the landscape of licensed options in the UK.

One practical note on eligibility once you are ready: the licensed private threshold is a BMI of 30 or above, or 27 or above if you have at least one weight-related condition such as hypertension or high cholesterol. Lower thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone is never the whole story, a prescriber weighs up the full clinical picture.

Step 3: contraception, pregnancy and the related guidance you should know

Because breastfeeding and recent pregnancy often overlap with questions about contraception, it is worth covering this clearly. The NHS England guidance on weight-management injections notes that for tirzepatide specifically, women taking the oral contraceptive pill should add a non-oral method of contraception (such as condoms) for the first four weeks of treatment and for four weeks after each dose increase. This is because Mounjaro slows gastric emptying, which can reduce how reliably the pill is absorbed. Patches, implants and hormonal coils are not affected in the same way.

For women who are thinking about conceiving in the future, tirzepatide is not recommended during pregnancy. The MHRA advises using effective contraception throughout treatment and for a wash-out period before trying to conceive, your prescriber will advise on the specific gap. If a pregnancy occurs while on treatment, stop the medicine and speak to a doctor promptly. If you have broader questions about whether this medicine is right for you, our page on whether taking Mounjaro is safe is worth reading alongside this page for fuller context.

HRT users should also know that NHS England suggests considering transdermal HRT forms (patches or gels rather than tablets) while on tirzepatide, for the same gastric-emptying reason. This is worth raising with a GP if it applies to you.

Step 4: when to get medical help, and how to report concerns

If you have already taken Mounjaro while breastfeeding, even unknowingly, speak to your GP or midwife promptly rather than waiting. Monitor your infant for any unusual symptoms and tell the healthcare professional exactly what dose you took and when. Side effects of tirzepatide in adults include nausea, vomiting, diarrhoea and, more rarely, acute pancreatitis, characterised by severe stomach pain that may spread to the back. These are adult data; what they mean for an infant exposed through breast milk is unknown, which is precisely why the guidance is precautionary. If you want a fuller picture of the evidence before speaking to a prescriber, our pages covering whether Mounjaro is safe and whether Mounjaro is safe to use bring together the key clinical considerations in one place.

Suspected side effects (including those in an infant you believe may be connected to a medicine) can be reported through the MHRA's Yellow Card scheme. You can also report a concern about a medicine sold or supplied in a way that seems inappropriate. Unusual GI symptoms like persistent discomfort are among the things our team fields questions about; you can read specifically about what causes the Mounjaro burp as one example of how the GI effects present in practice.

When you are ready to explore treatment after breastfeeding ends, the process at nume starts with a free clinical consultation, reviewed the same day by a real prescriber, not automated software. You can check your eligibility and start that consultation here. If you have questions in the meantime, our support team is available seven days a week.